MediGene AG (MDG1 F) stock market data APIs
€0.0703
-0(-0%)
as of January 16, 2026
Try our APIs with
free plan!
MediGene AG Financial Data Overview
Price chart is built with
Anychart
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Prev. Close
0.0703
Open
0.0675
High
0.071
Low
0.0671
52 wk Range
0.0192-2.045
Market Cap
1 038 K
Shares Outstanding
14 738 K
Revenue
7 446 K
EPS
-0.34
Beta
1.07
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MediGene AG data using free add-ons & libraries
Get MediGene AG Fundamental Data
MediGene AG Fundamental data includes:
- Net Revenue: 7 446 K
- EBITDA: -14 781 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-16
- EPS/Forecast: -1.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MediGene AG News
New
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
VALNEVA Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Di...
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
Lead program MDG1015 on track for CTA/IND approval in 2H 2024Prioritization of pipeline to accelerate the advancement of Medigene’s maturing KRAS-libraryProjected cash runway extended to Q1 2025. Ex...
Medigene amends 2023 financial guidance
Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the dis...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
Planegg/Martinsried, November 4, 2023.Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
